ArticleAnnals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia2026
Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases.
Article in Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis multi-institutional study investigated the clinical and prognostic significance of serum p53 antibody (s-p53-Ab) titers in patients with s-p53-Ab-positive esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemotherapy (NAC).
methodsWe analyzed 637 patients who underwent surgery at 15 institutions. Patients were divided into upfront surgery (n = 375) and NAC (n = 262) groups and stratified into high-titer (≥9.82 ng/mL) and low-titer (>1.30 to <9.82 ng/mL) groups.
resultsIn the upfront surgery group, high-titer patients had significantly worse relapse-free survival (P = 0.046) and overall survival (P = 0.024) than low-titer patients. In contrast, no significant survival differences were observed by titer after NAC, and the poorer prognosis associated with high s-p53-Ab titers in the upfront surgery cohort was not seen after NAC. Subgroup analyses of stage II and III disease showed similar, nonsignificant trends toward improved outcomes in high-titer patients after NAC.
conclusionsThese findings suggest that high s-p53-Ab titers are associated with a poor prognosis in patients undergoing upfront surgery. Although these observations did not reach statistical significance, patients with high titers may potentially benefit from NAC, indicating its potential therapeutic value in those with a strong p53 antibody response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.